Humasis Co. Ltd (205470) - Total Assets
Based on the latest financial reports, Humasis Co. Ltd (205470) holds total assets worth ₩339.69 Billion KRW (≈ $230.21 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Humasis Co. Ltd to assess how comfortably operating cash covers total debt obligations.
Humasis Co. Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's total assets have evolved over time, based on quarterly financial data. See 205470 book value for net asset value and shareholders' equity analysis.
Humasis Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Humasis Co. Ltd's total assets of ₩339.69 Billion consist of 64.0% current assets and 36.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.47 Billion | 0.0% |
| Accounts Receivable | ₩4.48 Billion | 1.4% |
| Inventory | ₩8.85 Billion | 2.7% |
| Property, Plant & Equipment | ₩69.74 Billion | 21.0% |
| Intangible Assets | ₩1.41 Billion | 0.4% |
| Goodwill | ₩3.23 Billion | 1.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 205470 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humasis Co. Ltd's current assets represent 64.0% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.0% of total assets.
Humasis Co. Ltd Competitors by Total Assets
Key competitors of Humasis Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Humasis Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.71 | 4.40 |
| Quick Ratio | 2.40 | 2.60 | 3.31 |
| Cash Ratio | 0.00 | 0.12 | 0.00 |
| Working Capital | ₩132.95 Billion | ₩137.38 Billion | ₩32.88 Billion |
Humasis Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Humasis Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | ₩331.92 Billion |
| Market Capitalization | $156.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Humasis Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Humasis Co. Ltd's assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Humasis Co. Ltd (2016–2024)
The table below shows the annual total assets of Humasis Co. Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩331.92 Billion ≈ $224.93 Million |
-4.43% |
| 2023-12-31 | ₩347.31 Billion ≈ $235.37 Million |
-25.72% |
| 2022-12-31 | ₩467.53 Billion ≈ $316.84 Million |
+37.22% |
| 2021-12-31 | ₩340.71 Billion ≈ $230.90 Million |
+398.50% |
| 2020-12-31 | ₩68.35 Billion ≈ $46.32 Million |
+87.32% |
| 2019-12-31 | ₩36.49 Billion ≈ $24.73 Million |
+6.40% |
| 2018-12-31 | ₩34.29 Billion ≈ $23.24 Million |
+21.08% |
| 2017-12-31 | ₩28.32 Billion ≈ $19.19 Million |
+133.58% |
| 2016-12-31 | ₩12.13 Billion ≈ $8.22 Million |
-- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more